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Abstract Expectations are high that increasing knowledge
of the genetic basis of cardiovascular disease will eventu-
ally lead to personalised medicine—to preventive and
therapeutic interventions that are targeted to at-risk indi-
viduals on the basis of their genetic profiles. Most
cardiovascular diseases are caused by a complex interplay
of many genetic variants interacting with many non-genetic
risk factors such as diet, exercise, smoking and alcohol
consumption. Since several years, genetic susceptibility
testing for cardiovascular diseases is being offered via the
internet directly to consumers. We discuss five reasons why
these tests are not useful, namely: (1) the predictive ability
is still limited; (2) the risk models used by the companies
are based on assumptions that have not been verified; (3)
the predicted risks keep changing when new variants are
discovered and added to the test; (4) the tests do not
consider non-genetic factors in the prediction of cardiovas-
cular disease risk; and (5) the test results will not change
recommendations of preventive interventions. Predictive
genetic testing for multifactorial forms of cardiovascular
disease clearly lacks benefits for the public. Prevention of
disease should therefore remain focused on family history
and on non-genetic risk factors as diet and physical activity
that can have the strongest impact on disease risk,
regardless of genetic susceptibility.
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Expectations are high that increasing knowledge of the
genetic basis of cardiovascular disease will eventually lead
to personalised medicine—to preventive and therapeutic
interventions that are targeted to at-risk individuals on the
basis of their genetic profiles [1, 2]. Encouraged by these
expectations, many companies already offer predictive
genetic testing, mostly via the internet and directly accessing
thegeneralpublic.Whileintuitivelyitisclearthatthesedirect-
to-consumergenetictestsaretoopremature,itisachallengeto
appreciate the seemingly conflicting claims.
Genome-based predictive testing and personalised med-
icine already exists for monogenic forms of cardiovascular
disease. In the long-QT syndrome in particular, the genetic
substrate impacts on prognosis and therapeutic choices.
Furthermore, there is sound evidence that pre-symptomatic
genetic testing in inherited primary arrhythmia syndromes
leads to prophylactic therapy in a substantial number of
patients [3]. In diseases without an easily discernable
arrhythmogenic substrate such as familial idiopathic ven-
tricular fibrillation, genetic testing might be the only way to
identify individuals at risk [4]. In hypertrophic cardiomy-
opathy, genetic cascade testing is a cost-effective way to
identify relatives at risk and for primary prevention of
sudden cardiac death [5, 6]. Counselling and testing take
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multidisciplinarycardiogeneticsoutpatientclinics[7]. Finally,
cascade testing for familial hypercholesterolaemia is current-
ly part of the Dutch population screening programme [8].
Most cardiovascular diseases are not monogenic but
caused by a complex interplay of many genetic variants
interacting with many non-genetic risk factors such as diet,
exercise, smoking and alcohol consumption. In these
complex forms of disease, each genetic variant has only a
marginal impact on disease risk, and therefore, genetic
prediction needs to consider multiple variants simultaneously.
Their effects are combined in risk models using similar
approaches, as for example, the Framingham Risk Score [9].
Empirical studies have demonstrated that the predictive
ability of genetic risk models is still very modest [10–13].
Despite the modest predictive ability, genetic suscepti-
bility testing for cardiovascular diseases has been offered
via the internet directly to consumers since several years. In
the early days, companies were offering cardiogenomic or
heart health tests, which covered a limited number of
genetic variants on the basis of which lifestyle recommen-
dations were decided. These recommendations were based
on each variant separately and usually included recommen-
dation of nutrition supplements that could be bought from
the same companies. The scientific basis for these tests was
very limited, predominantly because tested variants were
not robustly associated with disease risk at all or had very
low effect sizes [14]. Most of these companies are now out
of business, likely because for the same price others are
offering genome-wide scans that predict multiple diseases
simultaneously. For example, deCODEme tests six types of
cardiovascular diseases, including myocardial infarction,
abdominal aortic aneurysm, atrial fibrillation, peripheral
arterial disease, intracranial aneurysm and venous throm-
boembolism, in addition to about 45 other diseases and
traits. While the early commercial tests were based on
variants for which there was insufficient scientific basis
[14], companies like deCODEme, 23andMe, Navigenics and
Pathway Genomics have adopted high scientific standards for
the selection of genetic variants. Nevertheless, there are still
five reasons why also their tests are not useful for predicting
cardiovascular diseases at this moment.
First, the predictive performance of genetic variants for
complex diseases in general is limited because only a
relatively small number of the common variants involved
have been identified and their effect sizes are generally low
[15]. When tests only include a small number of variants
with small effect sizes, most tested individuals have
predicted risks that are very close to average. This implies
that the majority of individuals receive approximately the
same predicted risk, which consumers never realise,
certainly not before buying the test. While the use of
genome-wide scans suggests that prediction is based on a
larger number of variants for each disease, this frequently is
not the case. For example, deCODEme predicts abdominal
aneurysm and peripheral artery disease on one genetic
variant, atrial fibrillation on two, venous thrombosis and
intracranial aneurysm on three and myocardial infarction on
only seven variants and also 23andMe predicts myocardial
infarction risk on the basis of one chromosome 9 variant
alone (accessed 17 August 2010). It is clear that many more
variants need to be identified to achieve appreciable
predictive ability [16].
Second, the risk models used by the companies are based
on assumptions that have not been verified. Companies do
not obtain predicted risks from empirical studies, but rather
calculate individual risks by multiplying a population
average risk with the combined effects of the variants
tested. More frequently than before, companies use age-
and sex-specific average risks from epidemiological stud-
ies, but sometimes appropriate data are not available [17].
In addition, the odds ratios used in the calculation are
obtained from meta-analyses of case–controls studies,
which may overestimate the effects that are found in
unselected populations. And finally, the algorithms used
to calculate individual risks assume that genetic variants
inherit independently and that their combined effects follow
from multiplying the individual effects. While this may be
the best strategy to date, it almost guarantees inaccurate risk
estimates.
Third, predicted risks keep changing when new variants
are discovered and added to the test. For consumers, this
may imply that they are at increased risk of disease at one
moment and at decreased risk at the next, which is
confusing when the test result should impact decisions
about prevention or treatment. Updating type 2 diabetes
risk from 1 to 18 variants, we showed that half of the
population changed at least once from decreased to
increased risk or vice versa [18]. Thirty percent changed
risk categories at least twice. Risks generally change when
risk models are updated, but with the current speed of gene
discoveries from genome-wide association studies, risk
predictions may change too frequently to be of any practical
utility.
Fourth, current commercial tests do not consider non-
genetic factors in the prediction of cardiovascular disease
risk. Several studies have shown that genetic risk models
have substantially poorer predictive ability than conven-
tional risk models based on clinical measures, lifestyle
factors and family history and that genetic variants do not
further improve prediction of disease beyond these risk
factors [10–12, 19]. Recently, there has been substantial
debate about the clinical utility of testing a variant in 9p21,
a locus that has been consistently associated with cardio-
vascular conditions. Yet, also robustly associated variants
do not necessarily improve prediction. The per-allele odds
86 Neth Heart J (2011) 19:85–88ratio of 9p21 rs10757278 for risk of myocardial infarction
is 1.26 [20], not spectacularly higher than many other
variants, and two prospective studies showed that this
polymorphism, as expected, did not markedly improve
prediction of cardiovascular disease beyond traditional non-
genetic risk factors [21, 22].
And finally, the results of direct-to-consumer cardiovas-
cular genetic tests will not change recommendations of
preventive interventions. Many preventive strategies such
as healthy diet, physical activity, no smoking and moderate
alcohol consumption are recommended to everyone, irre-
spective of one’s exact cardiovascular disease risk. Some
individuals may need to change their diet because of a
genetic predisposition to cardiovascular disease, others
because of type 2 diabetes, osteoporosis or cancer. Claims
that genetic testing may enhance motivation and empower
prevention [23] are not substantiated by empirical evidence,
and evidence is also lacking for the preventive prescription
of medication, such as aspirins or statins.
When genetic tests are unable to usefully predict
cardiovascular disease to date, should we be concerned
about these commercial developments? On the one hand,
yes, because at least it may unnecessarily increase the
workload of health care professionals. A recent survey
showed that half of the individuals who bought a
commercial test and three quarters of those who would
consider buying one did or would consult a physician for
help interpreting the results [24]. Some physicians even
encourage their patients to use these tests (which are costly
and not reimbursed), sharing the expectations of consumers
that results will guide treatment. On the other hand, there
are no appropriate empirical studies that demonstrate that
these tests also have adverse psychological consequences
for consumers, also because consumers’ experiences with
the early commercial tests cannot be simply extrapolated to
these genome-wide scans. It is not clear whether consumers
can handle and appropriately interpret all risk information
from genome-wide scans, and whether they understand the
relative importance of genetic information in contrast to
non-genetic risk factors, particularly those lifestyle factors
that can be changed. It has been suggested that individuals
who learn that they are at increased genetic risk of disease
may adopt fatalistic beliefs, thinking that there is nothing
that they can do to prevent disease because it is already ‘in
their genes’ or that those who learn that they are at
decreased risk feel reassured and believe that in terms of
their lifestyle they can do what they like because they are
genetically protected.
In conclusion, most genetic tests for complex cardiovas-
cular disease have minimal predictive ability and no clear
benefits for consumers. Also for the future, it is uncertain
whether DNA testing for cardiovascular diseases will yield
useful information to guide decisions about preventive or
therapeutic interventions [25, 26]. There will likely be
promising exceptions, also for complex diseases. For
example, in pharmacogenomics, where genetic variants
are investigated for their impact on the degree of efficacy or
the toxicity of medications, genetic testing may become
useful to personalise medication regimens and doses. Yet, if
such applications do prove useful, these genetic tests will
undoubtedly be offered through the medical clinics and be
reimbursed.
We have provided five reasons cardiologists can use to
explain to patients why the direct-to-consumer cardiovas-
cular tests are not useful. This information may hopefully
lead to more realistic expectations about the impact of
genetic variants on disease risk and put the focus of
attention back to family history and to the non-genetic risk
factors, diet and physical activity, which can have the
strongest impact on disease risk, regardless of genetic
susceptibility. Counselling and testing for monogenetic
cardiovascular diseases should remain in the medical
setting and should only be provided by those professionals
that are knowledgeable and experienced in this field.
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